Kronos Bio Analyst Ratings
Kronos Bio Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 08/21/2023 | 525% | HC Wainwright & Co. | $10 → $9 | Maintains | Buy |
| 04/17/2023 | 594.44% | HC Wainwright & Co. | → $10 | Reiterates | → Buy |
| 11/18/2022 | 594.44% | HC Wainwright & Co. | $36 → $10 | Maintains | Buy |
| 11/10/2022 | 872.22% | Goldman Sachs | $25 → $14 | Maintains | Buy |
| 11/09/2022 | 386.11% | Piper Sandler | $13 → $7 | Maintains | Overweight |
| 09/14/2022 | 733.33% | Berenberg | → $12 | Initiates Coverage On | → Buy |
| 05/24/2022 | 1497.22% | Goldman Sachs | $35 → $23 | Maintains | Buy |
| 05/23/2022 | 802.78% | Piper Sandler | $30 → $13 | Maintains | Overweight |
| 02/28/2022 | 1983.33% | Piper Sandler | $50 → $30 | Maintains | Overweight |
| 11/10/2021 | 2400% | HC Wainwright & Co. | $35 → $36 | Maintains | Buy |
| 06/24/2021 | 2330.56% | HC Wainwright & Co. | → $35 | Initiates Coverage On | → Buy |
| 11/03/2020 | — | Cowen & Co. | Initiates Coverage On | → Outperform | |
| 11/03/2020 | 3025% | Goldman Sachs | → $45 | Initiates Coverage On | → Buy |
| 11/03/2020 | 3372.22% | Piper Sandler | → $50 | Initiates Coverage On | → Overweight |
| 日期 | 上行/下行 | 分析公司 | 目標價格變化 | 評級變化 | 上一次/當前評級 |
|---|---|---|---|---|---|
| 2023年08月21日 | 525% | HC Wainwright公司 | $10→$9 | 維護 | 買 |
| 04/17/2023 | 594.44% | HC Wainwright公司 | →$10 | 重申 | →購買 |
| 2022年11月18日 | 594.44% | HC Wainwright公司 | $36→$10 | 維護 | 買 |
| 2022年11月10日 | 872.22% | 高盛 | $25→$14 | 維護 | 買 |
| 11/09/2022 | 386.11% | 派珀·桑德勒 | $13→$7 | 維護 | 超重 |
| 09/14/2022 | 733.33% | 貝倫伯格 | →$12 | 開始承保 | →購買 |
| 2022年05月24日 | 1497.22% | 高盛 | $35→$23 | 維護 | 買 |
| 2022年05月23日 | 802.78% | 派珀·桑德勒 | $30→$13 | 維護 | 超重 |
| 02/28/2022 | 1983.33% | 派珀·桑德勒 | $50→$30 | 維護 | 超重 |
| 2021年11月10日 | 2400% | HC Wainwright公司 | $35→$36 | 維護 | 買 |
| 06/24/2021 | 2330.56% | HC Wainwright公司 | →$35 | 開始承保 | →購買 |
| 11/03/2020 | - | 考恩公司 | 開始承保 | →跑贏大盤 | |
| 11/03/2020 | 3025% | 高盛 | →$45 | 開始承保 | →購買 |
| 11/03/2020 | 3372.22% | 派珀·桑德勒 | →$50 | 開始承保 | →超重 |
What is the target price for Kronos Bio (KRON)?
Kronos Bio(KRON)的目標價是多少？
The latest price target for Kronos Bio (NASDAQ: KRON) was reported by HC Wainwright & Co. on August 21, 2023. The analyst firm set a price target for $9.00 expecting KRON to rise to within 12 months (a possible 525.00% upside). 6 analyst firms have reported ratings in the last year.
克羅諾斯生物公司(納斯達克代碼：KRON)的最新目標價是由HC Wainwright&Co.於2023年8月21日報道的。這家分析公司將目標價定為9美元，預計KRON將在12個月內上漲至(可能上漲525.00%)。6家分析公司在過去一年公佈了評級。
What is the most recent analyst rating for Kronos Bio (KRON)?
Kronos Bio(KRON)的最新分析師評級是多少？
The latest analyst rating for Kronos Bio (NASDAQ: KRON) was provided by HC Wainwright & Co., and Kronos Bio maintained their buy rating.
分析師對克羅諾斯生物公司(納斯達克代碼：KRON)的最新評級由HC Wainwright&Co.提供，克羅諾斯生物公司維持其買入評級。
When is the next analyst rating going to be posted or updated for Kronos Bio (KRON)?
Kronos Bio(KRON)的下一次分析師評級將於何時發佈或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Kronos Bio, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Kronos Bio was filed on August 21, 2023 so you should expect the next rating to be made available sometime around August 21, 2024.
分析師在進行了廣泛的研究後得出了股票評級，其中包括查閱公共財務報表，與Kronos Bio的高管和客戶交談，以及聽取收益電話會議。大多數分析師每三個月就會這樣做一次，所以你每年應該會得到每家公司每家公司的4個評級。Kronos Bio的上一次評級是在2023年8月21日提交的，所以你應該預計下一次評級將在2024年8月21日左右的某個時候提供。
Is the Analyst Rating Kronos Bio (KRON) correct?
分析師對Kronos Bio(KRON)的評級正確嗎？
While ratings are subjective and will change, the latest Kronos Bio (KRON) rating was a maintained with a price target of $10.00 to $9.00. The current price Kronos Bio (KRON) is trading at is $1.44, which is out of the analyst's predicted range.
雖然評級是主觀的，並將發生變化，但最新的Kronos Bio(KRON)評級維持不變，目標價在10.00美元至9.00美元之間。Kronos Bio(KRON)目前的交易價格為1.44美元，超出了分析師的預測區間。